Expert panelists Benjamin P. Levy, MD, and Suresh S. Ramalingam, MD, consider the role of osimertinib as frontline and second-line therapy for patients with EGFR-positive non-small cell lung cancer (NSCLC), given positive data from the FLAURA trial.
- 5 жыл бұрын
Osimertinib’s Role in EGFR+ Metastatic Lung Cancer
- Рет қаралды 1,588
Пікірлер: 1